Literature DB >> 30711330

Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.

Alberto Dalla Volta1, Anna Maria Formenti1, Alfredo Berruti2.   

Abstract

Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30711330     DOI： 10.1016/j.eururo.2019.01.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  5 in total

1.  Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

Authors:  Martina A Knechel; Keith T Schmidt; William D Figg
Journal:  Cancer Biol Ther       Date:  2019-09-18       Impact factor: 4.742

Review 2.  Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors:  George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal:  Nat Rev Drug Discov       Date:  2020-07-29       Impact factor: 84.694

3.  Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.

Authors:  Raymond S McDermott; John Greene; John McCaffrey; Imelda Parker; Sylva Helanova; Anne-Marie Baird; Ausra Teiserskiene; Marvin Lim; Helen Matthews; Olwyn Deignan; John Feeney; Pierre G Thirion; Stephen P Finn; Paul J Kelly
Journal:  Ther Adv Med Oncol       Date:  2021-09-06       Impact factor: 8.168

4.  Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice.

Authors:  Gherardo Mazziotti; Walter Vena; Rebecca Pedersini; Sara Piccini; Emanuela Morenghi; Deborah Cosentini; Paolo Zucali; Rosalba Torrisi; Silvio Sporeni; Edda L Simoncini; Roberto Maroldi; Luca Balzarini; Andrea G Lania; Alfredo Berruti
Journal:  J Bone Oncol       Date:  2022-03-09       Impact factor: 4.072

5.  Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients.

Authors:  Yasuhide Miyoshi; Masato Yasui; Sohgo Ttsutsumi; Takashi Kawahara; Ko-Ichi Uemura; Naruhiko Hayashi; Masahiro Nozawa; Kazuhiro Yoshimura; Hiroji Uemura; Hirotsugu Uemura
Journal:  BJUI Compass       Date:  2020-09-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.